Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Neurochemistry in Clinical Application
Neurological disorders cause untold suffering and financial burden to hundreds of thousands of people, not only to the patients, but also the relatives and society. As of today, though numerous scientists and clinicians have devoted their efforts to understand and combat these diseases, there is still no cure or satisfactory solution to the problems. Furthermore, the brain is the most essential organ of a human being. Realizing the importance of the brain, the president of the United States, George Bush, declared the 90s as the Decade of the Brain in January, 1992. Being in neuroscience research for almost three decades, I initiated, planned and organized the first international neuropharmac...
Handbook of Assay Development in Drug Discovery
The Handbook of Assay Development in Drug Discovery describes all the tools currently available for performing various assay techniques. Featuring troubleshooting advice for common problems from experienced assay developers, the vendor community, and scientists in the pharmaceutical industry, the book presents descriptions of methods, laboratory guidelines and protocols used to perform such methods, specific examples of each assay system, and troubleshooting tools. Designed as a guide to running an assay from start to finish, this is an ideal bench top companion for scientists involved in drug discovery screening, lead profiling, therapeutic target evaluation, and assay development and implementation.
Progress in Medicinal Chemistry
Annotation The complex and multidisciplinary nature of modern drug discovery is well illustrated in the six chapters of this volume that describe exciting developments in both newly emerging and mature areas of medicinal chemistry. Chapter 1 provides a comprehensive review of therapeutic applications of ligands for peroxisome proliferator-activated receptor gamma PPAR?, a key regulator of glucose and lipid homeostasis. Progress over the last decade on ligands that bind to central nicotinic acetylcholine receptors is timely reviewed in Chapter 2, with the emphasis on the a4ß2 subtype. Chapter 3 reviews inhibitors of PARP-1, the founding member of the family, with the focus on their therapeut...
Progress in Drug Research
Nikolaus Seiler, Benoit Duranton and Francis Raul: The polyamine oxidase inactivator MDL 72527.- Zhi Hong and Craig E. Cameron: Pleiotropic mechanisms of ribavirin antiviral activities.- Jie Hong Hu and Charles Krieger: Protein phosphorylation networks in motor neuron death.- James O. Schenk: The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.- Laszlo Prokai: Central nervous system effects of thyrotropin-releasing hormone and ist analogues: opportunities and perspectives for drug discovery and development.- David F. Horrobin: A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E).- Suprabhat Ray, Reema Rastogi and Atul Kumar: Current status of estrogen receptors.
Progress in drug research. 49.1997
From the contents: A- C. Brater and M. D. Murray: The effects of NSAIDs on the kidney A- G. Edwards and A. H. Weston: Latest developments in potassium channel modulator drugs A- M.R. Juchau and Y. Huang: Chemical teratogenesis in humans: Biochemical and molecular mechanisms A- S.P. Gupta: Studies on cardiovascular drugs A- G. Polak: Antifungal chemotherapy: An everlasting battle A- O. Valdenaire: New insights into the bioamine receptor family
Progress in Drug Research
S. Ren and E.J. Lien: CaCo-2 cell permeability vs human gastrointestinal absorption: QSPR analysis.- J.C.G. Halford and J.E. Blundell: Pharmacology of appetite suppression.- B. Olivier, W. Soudijn and I. van Wijngaarden: Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors.- D. Poyner, H. Cox, M. Bushfield, J.M. Treherne and M.K. Demetrikopoulos: Neuropeptides in drug research.- M. Kumari and M.K. Ticku: Regulation of NMDA receptors by ethanol.- H. Horikoshi, T. Hashimoto and T. Fujiwara: Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control.- Rosamund C. Smith and Simon J. Rhodes: Applications of developmental biology to medicine and animal agriculture.
Progress in Drug Research 56
Founded in 1959 by its current Editor, the series has moved from its initial focus on medicinal chemistry to a much wider scope. Today it encompasses all fields concerned with the development of new therapeutic drugs and the elucidation of their mechanisms of action, reflecting the increasingly complex nature of modern drug research. Invited authors present their biological, chemical, biochemical, physiological, immunological, pharmaceutical, toxicological, pharmacological and clinical expertise in carefully written reviews and provide the newcomer and the specialist alike with an up-to-date comprehensive list of prime references. Each volume of Progress in Drug Research contains fully cross-referencing indices which link the books together, forming a virtually encyclopaedic work. The series thus serves as an important, time-saving source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.
Muscarinic Receptors in Airways Diseases
What are the different muscarinic acetylcholine receptor subtypes and how are they distributed in the airways and molecular signalling mechanisms? What is their function in neurogenic and non-neurogenic control of the airways and in inflammatory mechanisms? How is their gene expression regulated? The great importance of muscarinic acetylcholine receptors for the pathophysiology and treatment of chronic inflammatory obstructive airways diseases calls for a comprehensive and integrated overview of the current knowledge to address such questions, to discuss the role of these receptor subtypes in diseases such as asthma and COPD, and to present novel perspectives on antimuscarinic drug development. The present book is the worthy result of this need. It points out innovative insights into the hitherto poorly understood role of postjunctional muscarinic M2 receptors in airway smooth muscle contraction and sheds some light on the novel concepts of antimuscarinic drug development, with special reference to the l
Pharmacological Regulation of Gene Expression in the CNS Towards an Understanding of Basal Ganglial Functions (1996)
This book focuses on dopamine-mediated regulation of gene expression within the striatum and associated regions of the central nervous system. It is an excellent review of experimental data on interactions between neuronal systems at systemic, cellular, and molecular levels. Each of the chapters, written by the world's leading scientists, provides an understanding of anatomy, neurochemistry, and cellular and molecular effects. Such an understanding sheds light on the pathophysiology of central disorders involving the basal ganglia and leads to new approaches for the treatment of diseases such as Parkinson's disease and schizophrenia, and also addictions to psychostimulants such as cocaine and amphetamines.
Phosphodiesterase Inhibitors
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting. - Utilizes actual testing and research of new PDE inhibitors - Valuable for researchers and students alike
